نتایج جستجو برای: relapsing remitting
تعداد نتایج: 10611 فیلتر نتایج به سال:
normal 0 false false false en-us x-none ar-sa microsoftinternetexplorer4 background: the efficacy of mitoxantrone induction therapy in rapidly worsening multiple sclerosis (ms) is well established. plasma exchange is also applied as an adjuvant in exacerbations of relapsing ms. the aim of this study was to compare the efficacy of combination therapy with mitoxantrone and plasma exchange versus ...
Alemtuzumab, a highly effective treatment for relapsing remitting multiple sclerosis (RRMS), induces lymphopenia especially of CD4+ T cells. Here, we report the atypical CD4+ T population behaviour of two patients with persistent disease activity despite repeated alemtuzumab treatments. Whereas lymphocytes count decreased and fluctuated accordingly to alemtuzumab administration, their CD4+ cell...
In patients with either relapsing-remitting or secondary-progressive multiple sclerosis, there were fewer new lesions/patient with natalizumab (0.7 and 1.1 with natalizumab 3 and 6 mg/kg every 28 days, respectively) than in the placebo group (9.6 new lesions/patient) over 6 months. There were also fewer relapses in the natalizumab groups than the placebo group. However, there were no changes in...
Raphael Schneider, MD Nathalie Arbour, PhD The topic of this Journal Club is a study by Bielekova et al.,1 who assessed whether daclizumab monotherapy reduces contrast-enhancing lesions (CEL) in patients with relapsing-remitting multiple sclerosis (RRMS). Furthermore, they evaluated the effects of daclizumab on clinical outcome measures and on NK cell populations in the CSF and blood of treated...
Raphael Schneider, MD Nathalie Arbour, PhD The topic of this Journal Club is a study by Bielekova et al.,1 who assessed whether daclizumab monotherapy reduces contrast-enhancing lesions (CEL) in patients with relapsing-remitting multiple sclerosis (RRMS). Furthermore, they evaluated the effects of daclizumab on clinical outcome measures and on NK cell populations in the CSF and blood of treated...
Background: It has been reported that liver function alterations occur in 8–38% of patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon-beta in controlled clinical trials or in prospective but non-controlled studies. We report herein a case of symptomatic liver dysfunction associated with two-year-period of regular interferon-beta-1a (Avonex®) intramuscular inje...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید